Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | ULK1 | O75385 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3792225 | 0.91 | TAS1R3 (0.41) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL3787047 | 0.90 | ERN1 (0.35) | CDK2ERN1HCRTR1HCRTR2BRAF | |
| SCHEMBL13228809 | 0.89 | SCN9A (0.36) | ERN1CNR2CNR1HCRTR1HCRTR2 | |
| SCHEMBL3793187 | 0.89 | KMT2A (0.40) | HDAC1HDAC6CNR2CNR1TAS1R3 | |
| SCHEMBL3789797 | 0.89 | HDAC1 (0.43) | HDAC1HDAC6CDK2CNR2CNR1 | |
| SCHEMBL3784891 | 0.88 | ERN1 (0.35) | HDAC1HDAC6ERN1HCRTR1HCRTR2 | |
| SCHEMBL3793511 | 0.87 | HDAC1 (0.38) | HDAC1HDAC6ULK1ERN1HCRTR1 | |
| SCHEMBL3795937 | 0.87 | TACR3 (0.36) | HDAC1HDAC6ERN1CNR2CNR1 | |
| SCHEMBL3793520 | 0.87 | CNR2 (0.36) | HDAC1HDAC6ERN1CNR2CNR1 | |
| SCHEMBL3786851 | 0.86 | ERN1 (0.33) | HDAC1HDAC6ERN1CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | claimed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | GENELABS TECHNOLOGIES, INC. | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204265-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections | OAT, HAVCR2, CPS1 | HDAC1 936/4885HDAC6 746/4885ULK1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.